Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

PARIS and NEW YORK and SAN FRANCISCO, Nov. 12, 2024 /PRNewswire/ -- Today, Formation Bio, together with OpenAI and Sanofi, introduced Muse, an advanced AI-powered tool developed to accelerate and ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.

“At Sanofi, we’re all in on AI,” Sanofi CEO Paul Hudson said in a press release. “And we are proud to partner with and invest in Formation Bio, whose AI-driven drug development vision and ...

Last month, Sanofi announced that it is collaborating with OpenAI and Formation Bio to boost its drug development projects through the use of artificial intelligence. The company, which did not ...

NEW YORK, June 26, 2024 /PRNewswire/ -- Formation Bio, a tech-driven and AI-native pharma company, announced today that it has raised $372MM of Series D financing. The financing was led ...

(Reuters) - AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi.